GlassScriptPhysician profile
Sherry N Ingraham
NPI 1700852605
$36,641.43
in general payments reported to CMS, 2019-2025
41 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,277 · 2021: $4,938 · 2022: $6,361 · 2023: $6,194 · 2024: $2,103 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,184 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,183.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15,733.88 | 2019-2025 | |
| Allergan, INC. | $5,489.11 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $4,352.75 | 2023 | Ycanth |
| Abbvie INC. | $2,191.82 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,650.16 | 2019-2025 | |
| Galderma Laboratories, L.P. | $927.91 | 2019-2025 | Aklief, Oracea, Twyneo |
| E.R. Squibb & Sons, L.L.C. | $547.29 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $521.80 | 2019-2024 | Tremfya |
| Amgen INC. | $511.36 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $487.18 | 2019-2025 | Adbry |
| Arcutis Biotherapeutics, INC. | $486.57 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $397.49 | 2023-2024 | Vtama |
| Genzyme Corporation | $339.65 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $285.05 | 2020-2025 | |
| Lilly USA, LLC | $262.00 | 2019-2024 | Olumiant, Taltz, Ebglyss |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Ingraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.